Evidence map›Paper›PMID 29570772›Full record

Trial reportThe British journal of dermatology2018

Risk of basal cell carcinoma in a randomized clinical trial of aspirin and folic acid for the prevention of colorectal adenomas.

M N Passarelli, E L Barry, D Zhang, P Gangar, J R Rees, R S Bresalier, G McKeown-Eyssen, M R Karagas, J A Baron

Open access · hybridAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The British journal of dermatology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.5field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Repurposing clinical trial data for skin cancer aetiology.The British journal of dermatology · 2018
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 2 countries.

M N PassarelliDepartment of Epidemiology, Geisel School of Medicine at Dartmouth, Hanover, NH, U.S.A.ORCID 0000-0002-6804-2528
E L BarryDepartment of Epidemiology, Geisel School of Medicine at Dartmouth, Hanover, NH, U.S.A.
D ZhangDepartment of Epidemiology, University of North Carolina, Chapel Hill, NC, U.S.A.
P GangarDepartment of Pediatrics, University of Arizona, Tucson, AZ, U.S.A.
J R ReesDepartment of Epidemiology, Geisel School of Medicine at Dartmouth, Hanover, NH, U.S.A.
R S BresalierDepartment of Gastroenterology, Hepatology, and Nutrition, University of Texas MD Anderson Cancer Center, Houston, TX, U.S.A.
G McKeown-EyssenEpidemiology Division, Dalla Lana School of Public Health, University of Toronto, ON, Canada.
M R KaragasDepartment of Epidemiology, Geisel School of Medicine at Dartmouth, Hanover, NH, U.S.A.
J A BaronDepartment of Epidemiology, Geisel School of Medicine at Dartmouth, Hanover, NH, U.S.A.
Dartmouth College · USThe University of Texas MD Anderson Cancer Center · USUniversity of Arizona · USUniversity of North Carolina at Chapel Hill · USUniversity of Toronto · CA

Funding

Relation Between In-utero Vitamin D and Immune Function in Early Childhood P20GM104416 · NIGMS · DARTMOUTH COLLEGE · PI KARAGAS, MARGARET RITA · 2013 to 2022
$23.7M
FOLATE, DNA METHYLATION AND CARCINOGENESIS IN THE BOWELR01CA059005 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BARON, JOHN ANTHONY · 1993 to 2013
$17.3M
NONMELANOMA SKIN CANCER IN NEW HAMPSHIRER01CA057494 · NCI · DARTMOUTH COLLEGE · PI KARAGAS, MARGARET RITA · 1993 to 2015
$10.9M
NCI NIH HHS R01 CA057494NCI NIH HHS R01 CA059005NIGMS NIH HHS P20 GM104416
6 · The paper itself

Abstract

backgroundAspirin may reduce the risk of several types of cancer.

objectivesTo evaluate if folic acid is associated with risk of basal cell carcinoma (BCC).

methodsBCC incidence was evaluated in a randomized, double-blind, placebo-controlled clinical trial of aspirin (81 mg daily or 325 mg daily for ~3 years) and/or folic acid (1 mg daily for ~6 years) for the prevention of colorectal adenomas among 1121 participants with a previous adenoma. BCC was confirmed by blinded review of pathology reports.

resultsOne hundred and four of 958 non-Hispanic white participants were diagnosed with BCC over a median follow-up of 13·5 years. Cumulative incidence of BCC was 12% [95% confidence interval (CI) 7-17] for placebo, 16% (95% CI 11-21) for 81 mg aspirin daily and 15% (95% CI 10-20) for 325 mg aspirin daily [hazard ratio (HR) for any aspirin 1·45 (95% CI 0·93-2·26); HR for 81 mg daily 1·57 (95% CI 0·96-2·56); HR for 325 mg daily 1·33 (95% CI 0·80-2·20)]. BCC risk was higher with aspirin use in those without previous skin cancer but lower with aspirin use in those with previous skin cancer (P

conclusionsNeither aspirin nor folic acid treatment had a statistically significant effect on risk of BCC. Subgroup analysis suggested that chemopreventive effects of nonsteroidal anti-inflammatory drugs may be specific to those at high risk for BCC.

Indexed as

AdenomaAgedAnti-Inflammatory Agents, Non-SteroidalAspirinBasal Cell CarcinomaColorectal NeoplasmsDose-Response Relationship, DrugDouble-Blind MethodDrug Therapy, CombinationFemaleFolic AcidFollow-Up StudiesHumansIncidenceMaleMiddle AgedAnti-Inflammatory Agents, Non-SteroidalAspirinFolic Acid

Identifiers

PMID29570772
PMCPMC6108912
OpenAlexW2790811276

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.